Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B-Reference-Cited by-同舟云学术

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B

Published:2013-09-24 Issue:5 Volume:98 Page:525-532
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Dietrich Barbara,Schiviz Alexandra,Hoellriegl Werner,Horling Frank,Benamara Karima,Rottensteiner Hanspeter,Turecek Peter L.,Schwarz Hans Peter,Scheiflinger Friedrich,Muchitsch Eva-Maria

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-013-1448-z.pdf

Reference21 articles.

1. Mukherjee S, Saha A, Biswas P, Mandal C, Ray K. Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B. Haemophilia. 2008;14:1076–81.

2. Bicocchi MP, Pasino M, Rosano C, Molinari AC, Della VE, Lanza T, et al. Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B. Haemophilia. 2006;12:263–70.

3. Giannelli F, Green PM, Sommer SS, Poon M, Ludwig M, Schwaab R, et al. Haemophilia B: database of point mutations and short additions and deletions—eighth edition. Nucleic Acids Res. 1998;26:265–8.

4. Mariani G, Di Paolantonio T, Baklaya R, Morfini M, Mannucci PM. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell’Emofilia. Transfusion. 1993;33:814–8.

5. Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang. 1994;67(Suppl 4):8–11.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and challenges in the purification of recombinant coagulation factors: A review;Journal of Chromatography A;2024-02

2. Recombinant Coagulation Factors and Thrombolytic Agents;Pharmaceutical Biotechnology;2024

3. Assessment of the percentage of full recombinant adeno-associated virus particles in a gene therapy drug using CryoTEM;PLOS ONE;2022-06-03

4. Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release;Molecular Therapy - Methods & Clinical Development;2020-06

5. Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B;International Journal of Molecular Sciences;2019-12-18